Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Ipilimumab/nivolumab/sunitinib

Interstitial nephritis, colitis and lack of efficacy: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Fukushima T, et al. Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation. International Cancer Conference Journal 11 : 286-291, No. 4, 2022. Available from: URL: https://www.springer.com/journal/13691 Fukushima T, et al. Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation. International Cancer Conference Journal 11 : 286-291, No. 4, 2022. Available from: URL: https://​www.​springer.​com/​journal/​13691
Metadaten
Titel
Ipilimumab/nivolumab/sunitinib
Interstitial nephritis, colitis and lack of efficacy: 2 case reports
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-38461-1

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Leflunomide

Case report

Methotrexate

Case report

AZD-1222